Portal de investigación
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Stahl, M
- DeVeaux, M
- Itzykson, R
- Ritchie, EK
- Sekeres, MA
- Majhail, N
- Barnard, J
- Podoltsev, NA
- Brunner, AM
- Komrokji, RS
- Bhatt, VR
- Al-Kali, A
- Cluzeau, T
- Santini, V
- Roboz, GJ
- Fenaux, P
- Litzow, M
- Fathi, AT
- Perreault, S
- Kim, TK
- Prebet, T
- Vey, N
- Verma, V
- Kobbe, G
- Bergua, J
- Serrano, J
- Gore, SD
- Zeidan, AM
Grupos
Abstract
Patients with primary refractory or relapsed acute myeloid leukemia (RR-AML) have very poor prognosis. Due to limited treatment options, some patients are treated with hypomethylating agents (HMAs) due to their tolerability. Little is known about the role of allogeneic hematopoietic stem cell transplantation (HSCT) following HMA therapy in this setting. We retrospectively analyzed an international cohort of 655 RR-AML patients who received HMA therapy to study patterns and outcomes with HSCT. Only 37 patients (5.6%) patients underwent HSCT after HMA therapy. The conditioning regimen was myeloablative in 57% and nonmyeloablative in 43%. Patients received matched unrelated donor, matched sibling, haploidentical and mismatched unrelated HSCT in 56%, 24%, 16% and 4% of cases, respectively. Acute GvHD and chronic GvHD were observed in 40% and 17% of patients. While the median OS for the entire cohort of patients was 15.3 months (95% CI 9.5 - 21.7 months), OS reached 29.7 months (95% CI 7.01 - not-reached) for patients who achieved a complete remission (CR) to HMA and no intervening therapies between HMA therapy and HSCT. Our study suggests that HMA therapy can effectively bridge some patients with RR-AML to HSCT. (C) 2018 American Society for Blood and Marrow Transplantation.
Datos de la publicación
- ISSN/ISSNe:
- 1083-8791, 1523-6536
- Tipo:
- Article
- Páginas:
- 1754-1758
- PubMed:
- 29649620
- Factor de Impacto:
- 2,087 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION ELSEVIER SCIENCE INC
Citas Recibidas en Web of Science: 5
Documentos
- No hay documentos
Filiaciones
Keywords
- Survival; Hypomethylating agents; Transplant; AML
Cita
Stahl M,DeVeaux M,MONTESINOS P,Itzykson R,Ritchie EK,Sekeres MA,Majhail N,Barnard J,Podoltsev NA,Brunner AM,Komrokji RS,Bhatt VR,Al A,Cluzeau T,Santini V,Roboz GJ,Fenaux P,Litzow M,Fathi AT,Perreault S,Kim TK,Prebet T,Vey N,Verma V,Kobbe G,Bergua J,Serrano J,Gore SD,Zeidan AM. Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study. Biol. Blood Marrow Transplant. 2018. 24. (8):p. 1754-1758. IF:3,599. (2).